Answers are grounded in this paper and cite their sources.
The study demonstrates the One4More strategy enhances neuronal resilience in Alzheimer's disease, suggesting innovative treatment implications.
Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder, is driven by multiple neurotoxic insults, including β-amyloid (Aβ) accumulation, hyperphosphorylated tau, apolipoprotein E4, inflammatory mediators, oxidative stress, and etc. Efforts to target each insult individually have proven challenging and have often yielded limited or inconsistent outcomes. Although combination therapies are being explored, the increasing complexity and potential for adverse interactions limit the practicality and overall benefit. An alternative strategy is to enhance the intrinsic neuronal defense mechanisms within the brain, enabling neurons to withstand a spectrum of insults simultaneously. Our recent study using the selective M2 receptor antagonist, AAD23, showed that reinforcing neuronal resilience delayed cognitive impairment and cholinergic neurodegeneration in GRK5-deficient Swedish APP mice without altering the Aβ burden or brain inflammation. These findings provide compelling evidence that strengthening intrinsic cellular defense can raise the neuronal tolerance threshold against multiple insults without directly targeting the insults. This finding supports a novel therapeutic paradigm, termed the “One4More” strategy, offering a unified approach to combating the multifaceted pathology of AD.
No takes yet. Share an insight, caveat, or question.
William Z. Suo (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: